Abstract
Type 1 Diabetes is an autoimmune disease most often associated with elevated and uncontrolled blood glucose levels. Therefore patient education and treatment compliance is often focused on disease maintenance through insulin treatment and blood glucose control. Unfortunately insulin therapy alone does not prevent the formation of diabetic complications. In order to find a real cure, the underlying pathology of the disease must be directly addressed. Diabetes is caused by the initial rapid destruction of the insulin producing beta cells of the pancreas by autoreactive T-cells. The autoimmune process is also maintained through dendritic cell auto-antigen presentation and the production of autoantibodies by B cells. Only through some forms of immunotherapy can the immune system be rebalanced to assure the survival of the remaining beta cell population. These techniques include cell ablation, competitive decoy auto-antigens, reduced cell activation, and auto-antigen introduction. Here we will review the current state of these different technologies and their progression through clinical trials for the treatment of type 1 diabetes.
Keywords: Autoimmune Disease, Type 1 Diabetes, Immunotherapy, dendritic cells (DC), antigen-presenting cells (APC), antigen tolerance, Altered peptide ligands (APL), cell depletion, insulin, anti-inflammatory cytokines
Current Pharmaceutical Design
Title: Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Volume: 17 Issue: 29
Author(s): Brett E. Phillips and Massimo Trucco
Affiliation:
Keywords: Autoimmune Disease, Type 1 Diabetes, Immunotherapy, dendritic cells (DC), antigen-presenting cells (APC), antigen tolerance, Altered peptide ligands (APL), cell depletion, insulin, anti-inflammatory cytokines
Abstract: Type 1 Diabetes is an autoimmune disease most often associated with elevated and uncontrolled blood glucose levels. Therefore patient education and treatment compliance is often focused on disease maintenance through insulin treatment and blood glucose control. Unfortunately insulin therapy alone does not prevent the formation of diabetic complications. In order to find a real cure, the underlying pathology of the disease must be directly addressed. Diabetes is caused by the initial rapid destruction of the insulin producing beta cells of the pancreas by autoreactive T-cells. The autoimmune process is also maintained through dendritic cell auto-antigen presentation and the production of autoantibodies by B cells. Only through some forms of immunotherapy can the immune system be rebalanced to assure the survival of the remaining beta cell population. These techniques include cell ablation, competitive decoy auto-antigens, reduced cell activation, and auto-antigen introduction. Here we will review the current state of these different technologies and their progression through clinical trials for the treatment of type 1 diabetes.
Export Options
About this article
Cite this article as:
E. Phillips Brett and Trucco Massimo, Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure, Current Pharmaceutical Design 2011; 17 (29) . https://dx.doi.org/10.2174/138161211798157603
DOI https://dx.doi.org/10.2174/138161211798157603 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Mesenchymal Stem Cells Targeting of Systemic Disorders in Age-related Macular Degeneration
Current Tissue Engineering (Discontinued) Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews Animal Models of Obesity and Metabolic Syndrome: Potential Tools for Alzheimers Disease Research
Current Alzheimer Research Recent Advances in Three-Component Cyclocondensation of Dimedone with Aldehydes and Malononitrile for Construction of Tetrahydrobenzo[b]pyrans Using Organocatalysts
Current Organic Synthesis Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Natural Products Modulating Autophagy Pathway Against the Pathogenesis of Diabetes Mellitus
Current Drug Targets Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease
Current Enzyme Inhibition Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets